<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210248</url>
  </required_header>
  <id_info>
    <org_study_id>NO 51/10</org_study_id>
    <nct_id>NCT01210248</nct_id>
  </id_info>
  <brief_title>Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <brief_summary>
    <textblock>
      The aim of this study is to check correlation between CYP2C19 genotype level of clopidogrel&#xD;
      metabolite in plasma and platelet inhibition status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      THE FIRST PHASE OF THE RESEARCH WILL INVOLVE PATIENTS RECRUITMENT AND INFORMED CONSENT FOR&#xD;
      GENETIC TESTING.THE MAJORITY OF PATIENTS WILL BE RECRUITED FROM EMERGENCY DEPARTMENT. EVERY&#xD;
      PATIENT WILL BE ASKED ABOUT HIS AND HIS PARENT'S ETHNICITY (ASHKENASI OR SEPHARDY JEW) AND&#xD;
      ADDITIONAL DRUGS HE TAKES. IF PATIENT AGREES TO PARTICIPATE IN THE STUDY , HIS BLOOD SAMPLE&#xD;
      WILL BE COLLECTED FOR 3 KINDS OF TESTS:&#xD;
&#xD;
        1. GENETIC (FOR CYP450 2C19)&#xD;
&#xD;
        2. PLATELET MAPPING TEST ( BY THROMBOELASTOGRAPH ASSAY)&#xD;
&#xD;
        3. CLOPIDOGREL INACTIVE METABOLITE DETERMINATION BY CHROMATOGRAPHIC METHOD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <primary_completion_date>January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">500</enrollment>
  <condition>PRIMARY FOCUS:PATIENT THAT TAKE CLOPIDOGREL</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BLOOD COLLECTION</intervention_name>
    <description>BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        THE RESEARCH WILL INVOLVE PATIENTS THAT TAKE CLOPIDOGREL AND READY TO GIVE INFORMED CONSENT&#xD;
        FOR GENETIC TESTING.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt; 18 OLD PATIENTS&#xD;
&#xD;
          -  THAT TAKE CLOPIDOGREL MORE THAN 1 WEEK&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PREGNANCY&#xD;
&#xD;
          -  CHRONIC LIVER DISEASES&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ADINA BAR HAIM, PhD</last_name>
    <phone>08-9779897</phone>
    <email>dinab@asaf.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>VICTORIA PAPIASHVILI, M.Sc</last_name>
    <phone>0577345973</phone>
    <email>victoriapapi@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zeriffin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ADINA BAR HAIM, PhD</last_name>
      <phone>08-9779897</phone>
      <email>dinab@asaf.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>VICTORIA PAPIASHVILI, M.Sc</last_name>
      <email>victoriapapi@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>September 26, 2010</study_first_submitted>
  <study_first_submitted_qc>September 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2010</study_first_posted>
  <last_update_submitted>September 27, 2010</last_update_submitted>
  <last_update_submitted_qc>September 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2010</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

